

John C Ashton

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1482838/john-c-ashton-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

991
citations

15
h-index

31
g-index

42
ext. papers

1,110
ext. citations

3.6
avg, IF

4.77
L-index

#	Paper	IF	Citations
38	The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. <i>Pharmacological Research</i> , 2021 , 175, 105986	10.2	3
37	Considerations for Whole-Slide Analysis of Murine Xenografts Experiments. <i>Journal of Histochemistry and Cytochemistry</i> , 2021 , 69, 627-631	3.4	
36	Synthesis and Biological Evaluation of (-) and (+)-Spiroleucettadine and Analogues. <i>ChemMedChem</i> , 2021 , 16, 1308-1315	3.7	
35	A radical hypothesis on the nature of sleep. <i>Medical Hypotheses</i> , 2020 , 134, 109434	3.8	
34	Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2019 , 865, 172749	5.3	5
33	Does the mouse tail vein injection method provide a good model of lung cancer?. <i>F1000Research</i> , 2019 , 8, 190	3.6	4
32	Is Cannabis Harmless? Focus on Brain Function. <i>Current Drug Research Reviews</i> , 2019 , 11, 33-39	2	6
31	What is medicinal cannabis?. <i>New Zealand Medical Journal</i> , 2019 , 132, 49-56	0.8	2
30	It has not been proven why or that most research findings are False. <i>Medical Hypotheses</i> , 2018 , 113, 27-29	3.8	3
29	The Rationale for Repurposing Sildenafil for Lung Cancer Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 367-374	2.2	12
28	The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β agonist Resistant Asthma. <i>Current Drug Targets</i> , 2018 , 19, 1344-1349	3	3
27	ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. <i>Scientific Reports</i> , 2017 , 7, 13955	4.9	15
26	Effect of cannabinoids on CGRP release in the isolated rat lumbar spinal cord. <i>Neuroscience Letters</i> , 2016 , 614, 39-42	3.3	5
25	Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. <i>Cancer Research</i> , 2015 , 75, 2400	10.1	87
24	Cannabinoid CB2 receptor immunolabelling in the healthy brain--still a live possibility. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014 , 387, 301	3.4	4
23	Neuroinflammation in ischemic brain injury as an adaptive process. <i>Medical Hypotheses</i> , 2014 , 82, 151-8	3.8	4
22	Validating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity. <i>Journal of Histochemistry and Cytochemistry</i> , 2014 , 62, 395-404	3.4	55

21	Cerebral hypoxia-ischemia causes cardiac damage in a rat model. <i>NeuroReport</i> , 2014 , 25, 796-800	1.7	3
20	Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. <i>European Journal of Pharmacology</i> , 2014 , 723, 294-304	5.3	10
19	Phylogenetic methods in drug discovery. <i>Current Drug Discovery Technologies</i> , 2013 , 10, 255-62	1.5	2
18	Neuropathic pain: an evolutionary hypothesis. <i>Medical Hypotheses</i> , 2012 , 78, 641-3	3.8	3
17	The atypical cannabinoid O-1602: targets, actions, and the central nervous system. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2012 , 12, 233-9	1.8	17
16	Synthetic cannabinoids as drugs of abuse. <i>Current Drug Abuse Reviews</i> , 2012 , 5, 158-68		25
15	The effect of delta 9-tetrahydrocannabinol on the extinction of an adverse associative memory. <i>Pharmacology</i> , 2008 , 81, 18-20	2.3	9
14	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. <i>Current Medicinal Chemistry</i> , 2008 , 15, 1428-43	4.3	66
13	Cannabinoids for the treatment of neuropathic pain: clinical evidence. <i>Current Opinion in Investigational Drugs</i> , 2008 , 9, 65-75		32
12	The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. <i>Current Neuropharmacology</i> , 2007 , 5, 73-80	7.6	212
11	Cannabinoids and cardiovascular disease: the outlook for clinical treatments. <i>Current Vascular Pharmacology</i> , 2007 , 5, 175-85	3.3	15
10	Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. <i>Neuroscience Letters</i> , 2007 , 412, 114-7	3.3	107
9	Cannabinoids for the treatment of inflammation. <i>Current Opinion in Investigational Drugs</i> , 2007 , 8, 373-84		37
8	Co-distribution of the cannabinoid CB1 receptor and the 5-HT transporter in the rat amygdale. <i>European Journal of Pharmacology</i> , 2006 , 537, 70-1	5.3	14
7	Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. <i>Neuroscience Letters</i> , 2006 , 396, 113-6	3.3	155
6	Mitochondrial ultrastructure and apoptotic protein expression in the vestibular nucleus complex following unilateral labyrinthectomy. <i>Brain Research</i> , 2005 , 1055, 165-70	3.7	3
5	Characterization of mitochondrial respiratory chain energetics in the vestibular nucleus complex. <i>Acta Oto-Laryngologica</i> , 2005 , 125, 422-5	1.6	
4	Immunohistochemical characterisation and localisation of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and the effects of unilateral vestibular deafferentation. <i>Brain Research</i> , 2004 , 1021, 264-71	3.7	24

3	Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum. <i>Cerebellum</i> , 2004 , 3, 222-6	4.3	18
2	Cannabinoid CB1 receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. <i>Neuroscience Letters</i> , 2004 , 364, 40-2	3.3	15
1	Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 44, 517-9	3.1	15